Career Possibilities Panel & Speed Networking: R&D Clinical, Regulatory, Patient Outcomes

In the world of business, careers are no longer linear or predictable. What was once a clearly sign-posted path as you progressed through milestones, a career road map is now circuitous presenting new challenges and opportunities at every bend. Life-long careers in one sector or one company are becoming a rarity as new technologies and shifting social norms disrupt traditional careers. Both employers and employees are seeking more diversity of experience, lifestyle flexibility and alternative paths.

This panel is designed to help you think about your career path and the different options that are open to you. The panel will have an informational interview type feel with panelists sharing their career paths, a look at what their job entails, transferrable skills for those looking to make a change, tips for uncovering opportunities, advice for others, and how to make brave leaps. 

Panelists include:

  • Julie Himes, Head of Rare Disease, Heme, Takeda Pharma
  • Michelle Luo, Global Program Leader, Gastroenterology Therapeutic Area, Takeda
  • Adora Ndu, Group Vice President, and Head of Worldwide Research and Development (WWRD) Strategy, Scientific Collaborations and Policy, BioMarin
  • Sarah Ringuette, Vice President, Regulatory Affairs, Elevation Oncology, Inc


Date and Time:  
February 16, 2022
6:15-7:45 PM EST

5 mins: Welcome
60 mins: Panel discussion
10 mins: Small group speed networking
5 mins: Learnings
10 mins: Small group speed networking




Members, Students, Postdocs: $5; Non-Members: $15

Given our mission is to promote women's development in STEM we would like to offer a free spot in our workshops to those in transition between jobs or who cannot afford the ticket price. Please contact [email protected] if you qualify.


Register Here


Check out the other events in this series


Panelists Bios

Adora Ndu, PharmD, JD, is Group Vice President, and Head of Worldwide Research and Development (WWRD) Strategy, Scientific Collaborations and Policy. At BioMarin, Dr. Ndu has also served in several leadership roles with global oversight and accountability, including as Vice President, and Head of Policy, Research, Engagement, and International, where she led a variety of Regulatory Affairs functions, including Patient Engagement, Outcomes Research, Regulatory Research and Intelligence, Global Regulatory Policy, and International Regulatory Affairs with oversight for regulatory strategy in Asia Pacific, Latin America, Eastern Europe, Middle East and Africa. Dr. Ndu is a regulatory affairs thought leader having served for many years at the Food and Drug Administration (FDA). While at FDA, Dr. Ndu was a Commander in the United States Public Health Service, and Director for FDA’s Division of Medical Policy Development where she led the development of a broad range of policies impacting the pharmaceutical and biotechnology industry. At FDA she also held leadership roles in the Office of Prescription Drug Promotion (OPDP), and was involved in FDA’s pharmacovigilance program. Dr. Ndu serves as an independent board director, and audit committee member at DBV Technologies (DBVT) and is also on the Board of Directors for the Alliance for Regenerative Medicine (ARM), as well as the Board of Visitors for Howard University College of Pharmacy. She is currently an Adjunct Lecturer at Johns Hopkins University, and was recognized in 2016 by the Maryland Daily Record as a Leading Woman. Adora received her Doctor of Pharmacy degree from Howard University College of Pharmacy and her JD from the University of Maryland Carey Law School. In her free time, Adora enjoys spending time with her husband (Obi) and her four children.

Sarah Ringuette has over 20 years of experience in pharmaceutical development including the past 10 in regulatory affairs. She recently joined Elevation Oncology as Vice President, Regulatory Affairs from Biohaven Pharmaceuticals where she was Executive Director of Regulatory Affairs and Head of Regulatory for the Kleo Pharmaceuticals subsidiary. Prior to Biohaven, she was a Principal in ICON's Strategic Regulatory Services consulting group and Global Regulatory Lead at Alexion and Bristol-Myers Squibb. She has led regulatory strategy for small molecules, biologics, and cell and gene therapies from pre-IND through market approval and post marketing in oncology, immunology, infectious disease, neurology, metabolic and compliment conditions and ophthalmology across rare, ultra rare and non-orphan indications. On her path to regulatory affairs, she was a Documentation Lead and Clinical Operations Lead at Bristol-Myers Squibb and served as a research assistant at both Memorial Sloan Kettering Cancer Center and a health outcomes policy firm. She has an MPH from Johns Hopkins University, a RAC from the Regulatory Affairs Professional Society and a BS from the George Washington University.